CN106491559B - 一种表面迭层自组装盐酸多柔比星共聚物纳米粒的制备方法 - Google Patents
一种表面迭层自组装盐酸多柔比星共聚物纳米粒的制备方法 Download PDFInfo
- Publication number
- CN106491559B CN106491559B CN201610907271.4A CN201610907271A CN106491559B CN 106491559 B CN106491559 B CN 106491559B CN 201610907271 A CN201610907271 A CN 201610907271A CN 106491559 B CN106491559 B CN 106491559B
- Authority
- CN
- China
- Prior art keywords
- plga
- nanoparticles
- solution
- dox
- doxorubicin hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 59
- 229960002918 doxorubicin hydrochloride Drugs 0.000 title claims abstract description 41
- 229920001577 copolymer Polymers 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 229920001661 Chitosan Polymers 0.000 claims abstract description 30
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims abstract description 27
- 229920000867 polyelectrolyte Polymers 0.000 claims abstract description 27
- 229920000615 alginic acid Polymers 0.000 claims abstract description 25
- 239000000783 alginic acid Substances 0.000 claims abstract description 25
- 229960001126 alginic acid Drugs 0.000 claims abstract description 25
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 25
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 25
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 58
- 239000000243 solution Substances 0.000 claims description 53
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 21
- 239000008367 deionised water Substances 0.000 claims description 20
- 229910021641 deionized water Inorganic materials 0.000 claims description 20
- 239000012071 phase Substances 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 17
- 238000005303 weighing Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 11
- 230000001804 emulsifying effect Effects 0.000 claims description 10
- 239000012074 organic phase Substances 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 9
- 238000000703 high-speed centrifugation Methods 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 abstract description 35
- 238000000034 method Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 8
- 239000002245 particle Substances 0.000 abstract description 7
- 238000001338 self-assembly Methods 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 238000003475 lamination Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 28
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 12
- 230000001186 cumulative effect Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 229960004679 doxorubicin Drugs 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940042317 doxorubicin liposome Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610907271.4A CN106491559B (zh) | 2016-10-17 | 2016-10-17 | 一种表面迭层自组装盐酸多柔比星共聚物纳米粒的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610907271.4A CN106491559B (zh) | 2016-10-17 | 2016-10-17 | 一种表面迭层自组装盐酸多柔比星共聚物纳米粒的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106491559A CN106491559A (zh) | 2017-03-15 |
CN106491559B true CN106491559B (zh) | 2021-04-02 |
Family
ID=58293894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610907271.4A Active CN106491559B (zh) | 2016-10-17 | 2016-10-17 | 一种表面迭层自组装盐酸多柔比星共聚物纳米粒的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106491559B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107126426B (zh) * | 2017-05-12 | 2020-05-12 | 辽宁大学 | 一种盐酸阿霉素自组装聚合物纳米粒及其制备方法 |
CN115444810B (zh) * | 2022-04-27 | 2023-10-13 | 贵州医科大学 | 一种载阿霉素纳米粒复合温敏凝胶的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1745848A (zh) * | 2005-07-29 | 2006-03-15 | 中国人民解放军第三军医大学 | 壳聚糖-海藻酸钠包裹幽门螺杆菌全菌蛋白微球及制备方法 |
CN101244275A (zh) * | 2008-03-05 | 2008-08-20 | 四川大学 | 骨病治疗修复长效缓释药物载体材料及其制备方法 |
-
2016
- 2016-10-17 CN CN201610907271.4A patent/CN106491559B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1745848A (zh) * | 2005-07-29 | 2006-03-15 | 中国人民解放军第三军医大学 | 壳聚糖-海藻酸钠包裹幽门螺杆菌全菌蛋白微球及制备方法 |
CN101244275A (zh) * | 2008-03-05 | 2008-08-20 | 四川大学 | 骨病治疗修复长效缓释药物载体材料及其制备方法 |
Non-Patent Citations (4)
Title |
---|
AlginateechitosanePLGA composite microspheres induce both innate and adaptive immune response through parenteral immunization in fish;Behera T等;《Fish & Shellfish Immunology》;20130630;全文 * |
基于天然高分子基元的阻隔层对磁性载药聚乳酸微球的控释作用;付昱等;《高等学校化学学报》;20121210(第12期);第2779页第2段,第2780页倒数第2-3段,第2781页倒数第1段 * |
壳聚糖/海藻酸钠自组装微囊的制备及表征;孙丽等;《农垦医学》;20130215(第01期);全文 * |
多柔比星PLGA纳米粒的处方工艺优化及体外释药行为研究;李洁丽等;《药学学报》;20130512(第05期);第760页右栏第5段,第764页左栏第2段 * |
Also Published As
Publication number | Publication date |
---|---|
CN106491559A (zh) | 2017-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102271659B (zh) | 伊立替康或盐酸伊立替康脂质体及其制备方法 | |
Krasnici et al. | Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels | |
Partha et al. | Buckysomes: fullerene-based nanocarriers for hydrophobic molecule delivery | |
Yang et al. | Chitosan coated vancomycin hydrochloride liposomes: characterizations and evaluation | |
CN113384530B (zh) | 一种多糖核心Nanocells及其制备方法与应用 | |
Lafi et al. | Aptamer-functionalized pH-sensitive liposomes for a selective delivery of echinomycin into cancer cells | |
CN110123761B (zh) | 一种仿生型高密度脂蛋白纳米粒及其制备和应用 | |
CN112773766B (zh) | 一种用于肿瘤治疗的脂质体递送系统及其制备方法与应用 | |
CN103120645A (zh) | 伊立替康或盐酸伊立替康脂质体及其制备方法 | |
CN103735509A (zh) | 一种米铂脂质体及其制备方法 | |
CN112402626B (zh) | 一种靶向肿瘤的生物伪装纳米递药系统及其制备方法 | |
CN103893123A (zh) | 一种脂质体-聚合物杂化纳米粒子及其制备方法和应用 | |
CN106491559B (zh) | 一种表面迭层自组装盐酸多柔比星共聚物纳米粒的制备方法 | |
CN106474064A (zh) | 一种蒿甲醚纳米脂质体及其制备方法与应用 | |
CN108619526B (zh) | 靶向还原敏感共载化疗药物与P-gp耐药逆转剂的纳米递送系统的制备方法 | |
Zhang et al. | Inducing controlled release and increased tumor-targeted delivery of chlorambucil via albumin/liposome hybrid nanoparticles | |
CN111001006A (zh) | 葫芦素b和氧化响应抗肿瘤前药共载仿生纳米粒 | |
Goswami et al. | A brief review on liposomal drug delivery system | |
Liang et al. | Multistage O2-producing liposome for MRI-guided synergistic chemodynamic/chemotherapy to reverse cancer multidrug resistance | |
CN108721643B (zh) | 一种用于免疫化疗的pH敏感脂质体 | |
CN104622810B (zh) | 一种稳定型难溶性抗肿瘤药物脂质体及其制备方法 | |
CN110898231A (zh) | 一种功能化拉洛他赛脂质体及其制备方法与应用 | |
EP3397244B1 (en) | Treatment of breast cancer using a combination of a cationic liposomal formulation of taxane, a non-liposomal formulation of taxane and a further active agent | |
CN101352418B (zh) | 吡柔比星或盐酸吡柔比星脂质纳米粒及其制备方法 | |
US10925831B2 (en) | Liposomal formulations of platinum-acridine anticancer agents and methods thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20181112 Address after: 211800 No. 69 Huangshanling Road, Pukou District, Nanjing City, Jiangsu Province Applicant after: JIANGSU HEALTH VOCATIONAL College Address before: 211036 Jiangjingyuan 26 # 302, Gulou District, Nanjing City, Jiangsu Province Applicant before: Liu Yuanfen Applicant before: Zheng Chunli Applicant before: He Xinyi |
|
TA01 | Transfer of patent application right | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231222 Address after: Room 2600, C27, Building 1, No. 35 Shishan Road, High tech Zone, Suzhou City, Jiangsu Province, 215000 Patentee after: Suzhou Haijia'er Technology Service Co.,Ltd. Address before: 211800 No. 69 Huangshanling Road, Pukou District, Nanjing City, Jiangsu Province Patentee before: JIANGSU HEALTH VOCATIONAL College |
|
TR01 | Transfer of patent right |